Abstract
Purpose of ReviewThe consequence of treatment for gynaecological cancers can cause sudden onset of intense menopausal symptoms, such as vasomotor symptoms, sexual dysfunction and emotional instability. Hormone replacement therapy (HRT) is often effective and can overcome these unpleasant and severe symptoms. However, data regarding its safety remains controversial. The big question therefore is whether HRT in gynaecological cancer survivors is possible. This is due to the fear of disease relapse. So, the purpose of this study was to review the evidence regarding cancer recurrence or death following use of HRT in survivors of gynaecological cancers.Recent FindingsFor endometroid endometrial cancer, most of the retrospective studies concluded that there was no increase in recurrence rate of endometrial cancers in HRT versus non-HRT users. HRT should be particularly avoided in epithelial ovarian tumours particularly serous cancers and serous borderline tumours due to expression of oestrogen receptors. Given the lack of evidence on the impact of HRT on recurrence and disease-free survival in survivors of cervical cancers, it would seem perfectly reasonable to prescribe HRT, particularly if they are premenopausal. Many clinical guidelines would consider the use of HRT to be contraindicated in breast cancer survivors based on limited RCT evidence.SummaryCurrent scientific data, comprising mainly of retrospective studies, suggest that recurrence rates and survival are comparable between HRT users and non-users. Women should know the paucity of safety data regarding the use of HRT. Wherever possible, non-hormonal alternatives to HRT should be considered in all women. If non-hormonal alternatives fail to achieve adequate control of symptoms, then it is possible to consider the HRT after careful counselling of the patient as well as involvement of the oncology team in the decision-making process. However, more robust randomised controlled trials are needed to get convincing data regarding the safety of HRT in gynaecological cancer survivors.
Highlights
This article is part of the Topical Collection on Advances in Gynaecologic Oncology Screening TechnologiesOne of the consequences of treating gynaecological and breast cancer in younger women is abrupt loss of ovarian function
Pre-invasive and early invasive cervical cancers are often treated with conservative surgery in young women, Hormone replacement therapy (HRT) is usually considered in advanced stages
HRT has never been linked to development of squamous cell carcinoma of the cervix which amounts to 80% of the cases
Summary
One of the consequences of treating gynaecological and breast cancer in younger women is abrupt loss of ovarian function. Advice on HRT use, in early-stage endometrial cancer is uncertain. There have been a few retrospective studies which concluded that there was no increase in recurrence rate of endometrial cancers in HRT versus non-HRT users [10–13, and). In a prospective trial with 49.1 months follow-up, Ayhan et al 2006 found no increase in recurrence rate of endometrial cancer after the use of HRT [14]. No other study has so far reported a detrimental effect of HRT in early-stage endometrial cancer survivors. Serous papillary and clear cell carcinomas are both aggressive variants of EC with a poor prognosis, even when diagnosed at an early stage They account for approximately 8% of all EC and occur mainly in postmenopausal women.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
